Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants With Gout

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AR 882 (Primary)
Indications Gout
Focus Registrational; Therapeutic Use
Acronyms REDUCE-1
Sponsors Arthrosi Therapeutics

Most Recent Events

17 Mar 2025 Status changed from planning to recruiting, according to an Arthrosi Therapeutics media release.
17 Mar 2025 According to an Arthrosi Therapeutics media release, trial is expected to be fully enrolled in 2025 and completed by the end of 2026.
17 Mar 2025 According to an Arthrosi Therapeutics media release, company announced dosing of first patient.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com